IM Cannabis Corp. (ticker: NASDAQ:IMCC), a leader in the medical cannabis sector, has released its fourth quarter and full-year 2023 financial results, highlighting both the challenges and strategic moves shaping the company's future. Despite a decrease in revenues due to the Israeli-Hamas war and slow-moving inventory, IM Cannabis remains optimistic about its growth potential, particularly in the German market, following upcoming cannabis legalization.
Key Takeaways
- IM Cannabis reports a challenging year with a decrease in annual revenues but sees a 7.5% increase in gross profit.
- The company is optimistic about growth in Germany, with a fully licensed EU-GMP processing facility and logistics center in place.
- In Israel, sales were impacted by the war, but regulatory changes are expected to facilitate market growth.
- A potential reverse merger with Kadimastem is announced to focus on core markets in Germany and Israel.
- The company plans to finance future operations through working capital resources and credit facilities.
Company Outlook
- IM Cannabis is focusing on the German market for accelerated growth in 2024, with legalization expected to boost demand.
- The company holds a leading position in sales and has established the necessary infrastructure for success in Germany.
Bearish Highlights
- Revenues for 2023 fell by 10% year-over-year, and the fourth quarter saw a 26% decline, primarily due to the Israeli-Hamas war and slow-moving stock.
- The net loss from continuing operations in 2023 was CAD10.2 million.
Bullish Highlights
- Despite revenue challenges, gross profit increased by 7.5% in 2023.
- The company has reduced G&A expenses by 49% and selling and marketing expenses by 6% for the year.
Misses
- Q4 2023 gross profit decreased by 68% compared to the previous year.
- Total operating expenses saw a significant reduction of 65% in the fourth quarter.
Q&A Highlights
- The supply chain in Israel is now stable after Q4 disruptions due to the war and health ministry issues.
- In Germany, no supply issues are present, but competition and pricing pressures are anticipated with market opening.
- Margins are expected to improve, although they may be influenced by external factors such as currency fluctuations.
IM Cannabis Corp. has faced a year marked by external challenges, including geopolitical tensions and market dynamics. Nevertheless, the company has made strategic decisions to position itself for future growth, particularly in the promising German market. With the legalization of cannabis in Germany and the opening of cannabis social clubs, IM Cannabis's EU-GMP certified facility and logistics center will be crucial assets in capitalizing on this new opportunity.
The company's strategic focus on private payers and flower products in Germany has already yielded a 180% growth in 2023, outpacing the market's 20% growth. This success, coupled with the anticipated regulatory changes in Israel, sets the stage for substantial growth in these core markets.
Financially, IM Cannabis has navigated through a tough year, with a decrease in revenues attributed to the Israeli-Hamas conflict and slower inventory turnover. However, the company's ability to increase its gross profit margin and reduce operating expenses demonstrates a resilient operational strategy.
Looking ahead, IM Cannabis plans to leverage its existing resources and credit facilities to finance its operations. The company's leadership has expressed confidence in the transition year of 2023 and is now directing its focus toward seizing growth opportunities in 2024, especially in Germany.
InvestingPro Insights
IM Cannabis Corp. (IMCC) has demonstrated resilience in the face of a challenging fiscal year, with strategic moves aimed at positioning the company for growth in core markets. Here are some InvestingPro Insights that shed light on the company's financial health and market performance:
InvestingPro Data:
- Market Cap (Adjusted): 6.23M USD, reflecting the company's current valuation in the market.
- Revenue LTM as of Q4 2023: 36.83M USD, indicating the total revenue generated in the last twelve months.
- 1 Month Price Total Return as of the latest data: 61.14%, showcasing a strong short-term performance in the company's stock price.
InvestingPro Tips:
- IMCC operates with a significant debt burden and is quickly burning through cash, which are important factors for investors to consider when evaluating the company's financial stability.
- Despite recent challenges, IMCC has seen a significant return over the last week, month, and three months, suggesting a positive trend in investor sentiment and market performance.
For investors seeking deeper analysis and additional insights, there are 11 more InvestingPro Tips available for IMCC at https://www.investing.com/pro/IMCC. These tips provide a comprehensive view of the company's financial metrics and market movements. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and gain access to valuable information that can inform your investment decisions.
Full transcript - IM Cannabis NAQ (IMCC) Q4 2023:
Operator: Good morning and welcome to IM Cannabis' Fourth Quarter 2023 and Full Year 2023 Earnings Conference Call. Today's conference call is being recorded. At this time, I would like to turn the conference over to Anna Taranko, Director of Investor and Public Relations.
Anna Taranko: Good morning and thank you operator. Joining me for today's call are IM Cannabis Chief Executive Officer, Oren Shuster; and Chief Financial Officer, Uri Birenberg. The earnings press release that accompanies this call is available on the Investor Relations section of our website at investors.imcannabis.com. Today's call will include estimates and other forward-looking information and statements including statements concerning future results of operations, economic conditions, and anticipated courses of action and are based on assumptions, expectations, estimates, and projections as the date hereof. This information may involve known and unknown risk, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such statements. Factors that could cause or contribute to such differences are described in detail in the company's most recent filings available on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov. Furthermore, certain non-IFRS measures will be referred to during this call and the term non-IFRS adjusted EBITDA loss will hereafter we referred to as adjusted EBITDA loss. Any estimates or forward-looking information or statements provided are accurate only as of the date of this call and the company undertakes no obligation to publicly update any forward-looking information or statements or supply new information regarding the circumstances after the date of this call. Please also note that all references on this call reflect currency in Canadian dollars. With that, I'd like to turn the call over to Oren Shuster, CEO of IM Cannabis. Oren please go ahead.
Oren Shuster: Thank you, Anna. Good morning everyone and thank you for joining us today. As you know we are a medical cannabis company based in Israel and Germany, which is why we will focus the call today on the regularization in Germany, the impact of the Israel-Hamas war, and in our Q4 results and the potential reverse-merger with Kadimastem, which we announced on February 28. When we take a look at Germany, 2023 was a roller coaster for the cannabis market. The year started out with extremely high expectations surrounding the proposed cannabis legalization. When the German Ministry of Health unveiled its initial legalization proposal in April of 2023, it was a big step forward, but still fell short of the initial legalization expectations. The German government spent the rest of the year reworking step one of the proposal focused on decriminalization, home growth, not-for-profit social clubs, and the rescheduling medical cannabis from narcotic, the most tightly regulated medication to regular prescription medication. While the implementation of the legalization was delayed several times, it cleared the final hurdle last Friday, March 22nd. The new legislation will enter into effect on April 1st with the opening of Cannabis social clubs expected on July 1st. Obviously, our German team is extremely excited to have the relative freedom to operate within the new regulatory structure. The size of the opportunity is massive. The general population is about 83 million people, more than double the population of California. Until the non-profit social clubs are up and running, the only legal way to buy cannabis in Germany will be in the pharmacy with a prescription. We believe if the medical market growth is the rescheduling of medical cannabis from narcotic to a regular prescription medication which will lower the barriers to market entry for new patients. Currently, one of the biggest bottlenecks in market growth is the prescription process. When prescribing narcotic, German physicians are required to document each patient and are subject to regular narcotic audits, whereas the prescription process of regular prescription medication is simplified removing this bottleneck. In addition, the rescheduling will ease the storage and transport regulations for both distributors as well as pharmacies. The prescription costs for self payers will also be reduced narcotic prescription as co-payment, which will no longer be applied under the new regulations. When we put on the beneficial changes brought about by the rescheduling together, we anticipate that the medical cannabis market growth will accelerate significantly as more new patients are expected to start entering the market. In 2020, we started laying the framework to become a top cannabis company in Germany. Since 2021, we have been in the top 10. We have a fully licensed EU-GMP cannabis processing facility, one of a handful in Germany licensed repack bulk. We distribute cannabis products through our EU-GDP licensed logistics center to any pharmacy in Germany within 24 hours. Having all our facilities EU-GMP and EU-GDP certified is so important because these are the highest certifications the European Union has to guarantee the safety of medical products. The structure behind both the EU-GMP and EU-GDP is lean agile and can be easily ramped up to meet the increasing market demand. By adding all these processes in-house, it enables us to maximize our margins while having independent full end-to-end control. We can and have been providing cannabis services to other cannabis brands in Germany as well. In November of 2022, we restructured and pivoted our strategy to focus exclusively on private payers and flowers, the market segment with the highest growth rates. Although, our objective was sustainable profitability, the results of this pivot was tremendous. When we take a look at December 2023 market data from Inside Health, it shows that we grew 180% in 2023, while the market only grew 20%. The German team posted the highest market share growth in the category to close out the year as a strong number five within the German cannabis flower distributors. We are number one in sales per SKU within the German market and have the highest growth in the market. These results clearly show the potential of our strategic people, driving accelerated growth while reducing costs. With our in-house EU-GMP facility, EU-GDP logistics facility support the accelerated growth we already delivered in 2023, we have the supply agreement in place to deliver further accelerated growth in 2024. With the framework, we have put in place and the experience we have gathered over the last four years, we believe that we are in an excellent position to take advantage of the momentous change in the cannabis category will go through in Germany. We have the infrastructure in place. We have the team and the supply agreements we need to grow further. Moving to Israel. The Israel-Hamas war started on October 7, while we can already see that its leading to an increase in patient and license number – and license numbers, it also played havoc with our business. For an example, the decrease in our October sales plus the interruption of our supply chain caused a 26% or CAD3.2 million decrease in our Q4 revenues. Also our shipping costs have increased by almost 100%. The currency fluctuations we talked about last quarter continued to affect our revenues. The total annual effect of the fluctuation is downside of approximately CAD2.5 million. In Q4. we continued cleaning out slow-moving stock by reducing prices that we started in Q3, while this helped drive incremental sales and volume, the lower prices impacted both our revenue and gross margin. On a positive note, in Q4, we reinforced our position as the number one in the premium market by relaunching two black market strains Jealousy and Bacio Gelato as well as two PICO strains, Jealousy number one and Bacio Gelato number four in addition to launching new PICO strain ups and down number five. As in Germany, in 2023, the Israel Ministry of Health started working on a regulatory overall, facilitating access to medical cannabis for patients with medical indications ranging from metastatic cancer to pain and PTSD. The proposal includes moving medical cannabis to first-line treatment as opposed to last-line treatment and touches on existing export regulations. Just yesterday, the Ministry of Health had a conference to disclose the expected time line and implementation of the new legislation. I will go into detail during our Q1 2024 call, as we anticipate that the regulatory change will drive substantial growth in the Israeli cannabis market. In summary, while the overall results did not meet our expectations, 2023 was a year of transformation. We are lean and agile business, able to take advantage of the accelerated growth expected of the rapidly evolving cannabis market in both Germany and Israel in 2024. I would now like to take you through the proposed reverse merger with Kadimastem. When we started our year of transformation last year, we were focused on two goals: achieving sustainable profitability and maximizing shareholder value. We massively restructured the entire operation in 2023 to minimize costs and maximize our efficiency and agility. We made considerable progress in this direction throughout the year. While this process significantly improved our company's financial health, it does not translate into increasing shareholder value. This was from and center while we have been looking for a way to deliver maximum value for our shareholder in the current situation, keeping all possibilities open. It drove the decision to initiate the potential reverse merger with Kadimastem. It delivers on our promise of maximizing shareholder value, while giving the legacy cannabis business the freedom to fully focus on just that. The cannabis business in Israel and Germany, two of the highest value medical markets, which are set to grow significantly this year. We expect that this process will accelerate the path to sustainable profitability of the cannabis business, which our shareholders will retain in addition to participating with 5% in Kadimastem business, which we believe has tremendous potential. With a focus on clinical stage cell therapy, they were recently approved by the FDA to conduct Phase IIa clinical trial. The next steps in the reverse merger process involved initiating robust due diligence, commencing work on the definitive agreement, as well as investigating the conditions, precedent and requirements of the CSC announcement. It is still too early to assess how long it will take until we sign a definitive agreement. To sum up, 2023, we see that while the shift in strategy was not necessarily the easiest decision, the results in Germany undoubtedly show that it was the right one. Between the fluctuation in currency and the Israeli-Hamas war in Q4, we did not see the results we expected in Israel this year. When I look at the overall results of 2023, I see that we are lean agile and well positioned to take advantage, not just of the growth expected by the organization in Germany, but in Israel as well. 2024 is the year we have been preparing for. In 2024, our focus will be clearly on Germany, where we are well positioned to deliver accelerated growth. We grew 180% in 2023. We are number one in sales this Q. We have the infrastructure and the team we need for success, as well as the supply agreement in place with the leader. I believe, this together, with a 12% participation in Kadimastem will deliver shareholder value. I will now turn the call over to our Chief Financial Officer, Uri Birenberg who will review our fourth quarter 2023 and full year financial results. Uri?
Uri Birenberg: Thank you, Oren. I will now provide an overview of Q4 2023 and the annual financial results for the company's continuing cannabis operations. As Oren already mentioned, Q4 was tremendously impacted by the Israeli-Hamas war, which is apparent in our revenues, as well as our expenses. Revenues for 2023 were $48.8 million compared to $54.3 million in 2022, a decrease of 10%. Revenues for the fourth quarter of 2023 were $10.7 million compared to $14.5 million, a decrease of 26%. The main part of the decrease on the fourth quarter about $3.2 million was due to the interruption of the supply chain cost by the Israeli-Hamas war and the slow-moving stock that was moved out at a lower price. Total dried flower sold in 2023 was approximately 8,609 kilograms with an average selling price of $5.14 per gram, compared to approximately 6,792 kilograms in 2022 with an average selling price of $7.12 per gram. The difference is mainly due to increased competition, within the retail segment and mid-range stock discounts to move out slow-moving stock. Total dried flower sold in the fourth quarter of 2023 was about 2,082 kilogram with an average selling price of $4.52 per gram, compared to about 2,334 kilograms in the fourth quarter of 2022, with an average selling price of $5.19 per gram. The decrease in average selling price was caused by increased competition within the retail segment, and mid-rate stock discounts to move out slow-moving stock. Gross profit for 2023 was $9.8 million compared to $9.2 million in 2022, an increase of 7.5%. Gross profit for the fourth quarter of 2023 was $0.8 million, compared to $2.6 million in the fourth quarter of 2022, a decrease of 68%. The downside is mainly attributed to the decrease in revenue -- cost by the war and the slow-moving stock that was moved out at a lower price and about $0.8 million cost of sale hit, due to inventory raise. Company fair value adjustment was about $1 million versus $2.1 million for the years ended 2023 and 2022. Gross margin before fair value adjustment in 2023 was 22% compared to 21% in 2022. Gross margin before fair value adjustment in the fourth quarter of 2023 was 10% compared to 19% in the fourth quarter of 2022, a decrease of 46%. G&A expenses in 2023 were $11 million compared to $21.5 million in 2022, a decrease of 49%. G&A expenses in the fourth quarter of 2023 were $3.3 million, compared to $9.8 million in the fourth quarter of 2022, a decrease of 66%. The decrease in the G&A expenses is attributed, mainly to impairment on year 2022 and restructuring and head count adjustment in 2023. Selling and marketing expenses in 2023 were $10.8 million, compared to $11.5 million in 2022, a decrease of 6%. Selling and marketing expenses in the fourth quarter of 2023 were $2.8 million, compared to $3.1 million in Q4 2022, a decrease of 10%, mainly due to a decrease in share-based compensation and restructuring. Total operating expenses in 2023 were $22.6 million, compared to $40 million in 2022. Total operating expenses for the quarter of 2023 were $6 million, compared to $13.3 million in the fourth quarter of 2022, a decrease of 65%. Non-IFRS adjusted EBITDA loss in 2023 was CAD8 million, compared to an adjusted EBITDA loss of CAD11.5 million in 2022, a decrease of 31%. Adjusted EBITDA loss in the fourth quarter of 2023 was CAD4.2 million compared to adjusted EBITDA loss of CAD1.9 million in the fourth quarter of 2022, an increase of 127%. Net loss from continuing operations in 2023 was CAD10.2 million compared to CAD24.9 million in 2022. Net loss from continuing operations in the fourth quarter of 2023 was CAD3.5 million compared to a net loss of CAD9.6 million in the fourth quarter of 2022. Diluted loss per share in 2023 was CAD0.74 compared to a loss of CAD3.81 per share in 2022. Diluted loss per share in the fourth quarter of 2023 was CAD0.25 compared to a basic loss of CAD2.94 per share and a diluted loss of CAD3.55 per share in the fourth quarter of 2022. As of the balance sheet, cash and cash equivalents as of December 31 2023 were CAD1.8 million compared to CAD2.4 million in December 31 2022. Total assets as of December 31 2023 were CAD48.8 million compared to CAD60.7 million in September 31 2022, a decrease of about 20%. The decrease is mainly attributed to inventory reduction of about CAD6.6 million, a reduction in other assets of CAD1.8 million and the reduction of noncurrent assets of about CAD3.5 million. Total liabilities as of December 31 2023 were CAD35.1 million compared to CAD36.9 million in December 31 2022, a decrease of about 5%. The decrease was mainly due to the reduction in trade payables of about CAD6.1 million. The company is planning to finance its operations from an existing and future working capital resources, as well as from available credit facilities and we'll continue to evaluate additional sources of capital and financing, as needed. I would like to turn the call back to Oren for closing remarks. Oren?
Oren Shuster: Thank you, Uri. While 2023 was a year of transition, the Israeli-Hamas war had a tremendous impact on our Q4 results from the revenue to the gross margin. The results were not those we expected. Looking forward to 2024, it is the year that we have been preparing for. In 2024, our focus will clearly be on Germany, where we are in excellent position to deliver accelerated growth. We grew 180% in 2023. We are number one in sales per SKU. We have the infrastructure and the team we need to succeed as well as the supply agreement in place, to deliver on our objectives in 2024. With that, I hand the call over to the operator to begin our question-and-answer session. Operator?
Operator: Thank you. [Operator Instructions] We have our first question from Aaron Grey. Aaron, please go ahead.
Q – Aaron Grey: Hi. And thanks very much for taking the question. And first off continue well wishes and thoughts for all those within the company, during these times. First question for me -- so just in terms of right, the potential spin-off and reverse merger, just at a high level, remind us in terms of like how we could think about where we stand today as it's still like LOI or definitive agreement, right? In terms of the investments you're planning with the existing legacy Israeli and German business, especially with the potential in Germany. So how should we think about the operations and plan, investment between as you're looking to do this high level of potential reverse merger and spin out? Thank you.
Oren Shuster: Okay. Hi. Thank you, Aaron for the question. So as we said, we signed a non-binding term sheet with Kadimastem, both them being public and we haven't signed a definitive agreement. The idea is that all the assets that belongs today to IMC will be -- will still belong to the shareholders -- existing shareholders of IMC. And it will be separated from the public vehicle, the structure is not final yet. So it's difficult for me to say exactly what will be the structure, and how it will look like, but the general idea is that all the rights will be served -- will be with the current shareholders.
Aaron Grey: Okay. All right. Great. Thanks that clarification.
Oren Shuster: I'm not sure that I answered the question, but.
Aaron Grey: No. That's fine there. So for Germany there, can you talk about the strategy in terms of helping to build kind of patient and doctor awareness on your guys, as I understand that you need to prescribe this specific brand, which is a little bit different than some of the other cannabis markets we just get a broad prescription. And you can just go buy the brand at the respective dispensary or pharmacy. So any plans there? And then also capacity and supply chain as you look to grow within Germany? Thank you.
Oren Shuster: Okay. So Germany was one of our -- the main target market for us from the beginning. And we invested in building the infrastructure so that Germany will be like a hub that we can bring significant quantity of product through this hub. We have in Germany the ability to get bulk or final products, and we have a very significant warehouse that we can store and distribute product. The capacity in the warehouse, it depends on the packaging, but it's more than 4 tons at any moment. So it's very significant because the product is moving. So I don't think that we have any limitation of the product given the market as it is. I think that, I don't see in the near future fully that we have a problem of utilization. We have enough capacity for the market as I see it.
Aaron Grey: Okay. Great. Appreciate the color and I'll now jump back in the queue.
Oren Shuster: I'm sorry you asked about supply. So we have already supply agreements in place to Germany. We are selling a product in the German market for some time. We have been prepared for the legalization. We extended our supply agreement and our suppliers are eager to supply product to Germany.
Aaron Grey: Okay. Great. Appreciate the color. And I'll now jump back in the queue.
Operator: Thank you, Aaron. Our next question is from Scott Fortune. Scott, please go ahead.
Unidentified Analyst: Hey. Good morning. This is Nick on for Scott. I just want to echo Aaron's (NYSE:AAN) comments. I hope everybody is staying safe out there. First one for me, just on the sourcing side, with the geopolitical issues still kind of playing out here, I wanted to get an update on the supply chain environment and if you've seen any discernible changes just on the sourcing side either in Israel or Germany? Thank you.
Oren Shuster: Okay. Thank you for the question. In Israel, we had significant issues of supply in Q4, because when the war started, there was a mess year with the Ministry of Health. So it created significant issues in the supply chain. And now everything is okay. The product is coming to Israel. And it's working properly. And with Germany there aren't any issues of supply, beside the fact that you have to be EU GMP certified. And we have done a few audits just lately to more suppliers to make sure that we won't have any supply issues.
Unidentified Analyst: Yeah. I appreciate that color. And then, the second one for me, just on the pricing side, with Germany now set to expand here and patients in Israel still growing, just wanted to get an update on the general pricing environment in both countries. Have you seen any notable changes in supply-demand economics and just general pricing? Any color there would be helpful.
Oren Shuster: The Israeli market is highly competitive. And we can see very clearly there is a decline in prices in many segments of the market. We are more focused on the premium segment. So we feel it less. But definitely everybody feels it in the market. And I don't think that we will see significant change in the near future. Regarding Germany, I think that the market will be -- my assumption is that the market will be highly competitive very similar to other markets and we will see also similar behavior, although there is a lot of supply that is waiting for the opening of the German mall. So it's a question in Germany, I think of how fast the market will evolve and the quantities, but still I believe that it will be a highly competitive market.
Unidentified Analyst: Got it. And then just last one for me on the inventory side. You called out moving stock which impacted pricing. Where are we in terms of clearing that out fully? And just your sense of the inventory and just the margin profile in 2024, as you kind of clear out the last bit of this lower cost inventory? Thank you.
Oren Shuster: So I think that our margins, I believe that our margins will improve. Obviously, there are many factors here. This year we have been impacted also by the currency. Most of the product that we are bringing is from Canada. So obviously, it was a negative impact. So there are a few external factors that I can't foresee, but I think that our focus on the premium segment will also leave us better margins. And regarding something that I missed about Germany I have to -- I want to say we already see products in Germany that are in very highly competitive prices and also below black market today in Germany. So I think that we will see significant down pressure in Germany as well and it will be very quick.
Unidentified Analyst: Got it. I appreciate the color, Oren. Thank you.
Oren Shuster: Thank you.
Operator: Are there any further questions? [Operator Instructions] Oren, I don't think there are any further questions.
Oren Shuster: Okay. Thank you, operator, and thank you all for joining our call today.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.